

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](http://FDI.Lab-SciCrunch.org) on Mar 31, 2025

## SOURCE

RRID:SCR\_005799

Type: Tool

---

### Proper Citation

SOURCE (RRID:SCR\_005799)

---

### Resource Information

**URL:** <http://smd.stanford.edu/cgi-bin/source/sourceSearch>

**Proper Citation:** SOURCE (RRID:SCR\_005799)

**Description:** SOURCE compiles information from several publicly accessible databases, including UniGene, dbEST, UniProt Knowledgebase, GeneMap99, RHdb, GeneCards and LocusLink. GO terms associated with LocusLink entries appear in SOURCE. The mission of SOURCE is to provide a unique scientific resource that pools publicly available data commonly sought after for any clone, GenBank accession number, or gene. SOURCE is specifically designed to facilitate the analysis of large sets of data that biologists can now produce using genome-scale experimental approaches Platform: Online tool

**Abbreviations:** SOURCE

**Resource Type:** production service resource, database, analysis service resource, data or information resource, data analysis service, service resource

**Defining Citation:** [PMID:12519986](https://pubmed.ncbi.nlm.nih.gov/12519986/)

**Keywords:** genomic, functional annotation, ontology, gene expression, gene, genome, statistical analysis, bio.tools, FASEB list

**Funding:** NIGMS ;  
NCI CA85129-04;  
NIGMS GM07365

**Availability:** Restricted

**Resource Name:** SOURCE

**Resource ID:** SCR\_005799

**Alternate IDs:** biotools:source, nlx\_149287

**Alternate URLs:**

<https://login.stanford.edu/idp/profile/SAML2/Redirect/SSO?execution=e1s1>,  
<https://bio.tools/source>

**Record Creation Time:** 20220129T080232+0000

**Record Last Update:** 20250331T060538+0000

---

## Ratings and Alerts

No rating or validation information has been found for SOURCE.

No alerts have been found for SOURCE.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 67 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Ravindranath R, et al. (2025) The Impact of Race, Ethnicity, and Sex on Fairness in Artificial Intelligence for Glaucoma Prediction Models. *Ophthalmology science*, 5(1), 100596.

Brown KGM, et al. (2024) Priority outcomes of pelvic exenteration for rectal cancer: a patient, carer, and clinician consensus. *The British journal of surgery*, 111(12).

Raichurkar P, et al. (2023) Research Priorities in Prehabilitation for Patients Undergoing Cancer Surgery: An International Delphi Study. *Annals of surgical oncology*, 30(12), 7226.

Braun T, et al. (2023) Mucosal transcriptomics highlight lncRNAs implicated in ulcerative colitis, Crohn's disease, and celiac disease. *JCI insight*, 8(14).

Claypool AL, et al. (2023) Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids. *JAMA health forum*, 4(5), e231080.

Stringfellow EJ, et al. (2022) Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis. *Science advances*, 8(25), eabm8147.

Lim TY, et al. (2022) Modeling the evolution of the US opioid crisis for national policy development. *Proceedings of the National Academy of Sciences of the United States of America*, 119(23), e2115714119.

Steffens D, et al. (2021) Feasibility and acceptability of a preoperative exercise program for patients undergoing major cancer surgery: results from a pilot randomized controlled trial. *Pilot and feasibility studies*, 7(1), 27.

Haven T, et al. (2021) Explaining variance in perceived research misbehavior: results from a survey among academic researchers in Amsterdam. *Research integrity and peer review*, 6(1), 7.

Wechsler ME, et al. (2020) SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. *Respiratory research*, 21(1), 264.

Menzies-Gow A, et al. (2020) DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. *Respiratory research*, 21(1), 279.

Birnbaum DJ, et al. (2019) XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. *Journal of clinical medicine*, 8(5).

Arfaoui A, et al. (2019) A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. *EMBO molecular medicine*, 11(10), e9930.

Wang K, et al. (2019) Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study. *Cancer medicine*, 8(2), 686.

Haven TL, et al. (2019) Perceptions of research integrity climate differ between academic ranks and disciplinary fields: Results from a survey among academic researchers in Amsterdam. *PLoS one*, 14(1), e0210599.

Fessl T, et al. (2018) Dynamic action of the Sec machinery during initiation, protein translocation and termination. *eLife*, 7.

Beck MW, et al. (2018) The global flood protection savings provided by coral reefs. *Nature communications*, 9(1), 2186.

Mei N, et al. (2018) A high-density scalp EEG dataset acquired during brief naps after a visual working memory task. *Data in brief*, 18, 1513.

Gilhooly DA, et al. (2018) The evaluation of risk prediction models in predicting outcomes after bariatric surgery: a prospective observational cohort pilot study. *Perioperative medicine (London, England)*, 7, 6.

Wang SH, et al. (2018) Hyperedge bundling: Data, source code, and precautions to modeling-accuracy bias to synchrony estimates. *Data in brief*, 18, 262.